Dynavax Technologies Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 405

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.2B

Dynavax Technologies General Information

Description

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Contact Information

Website
www.dynavax.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 2100 Powell Street
  • Suite 720
  • Emeryville, CA 94608
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Sanofi
Vertical(s)
Corporate Office
  • 2100 Powell Street
  • Suite 720
  • Emeryville, CA 94608
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dynavax Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Merger/Acquisition 10-Feb-2026 $2.2B Completed Profitable
17. Debt Refinancing 05-Mar-2025 Completed Generating Revenue
16. PIPE 31-Aug-2024 Completed Generating Revenue
15. Secondary Transaction - Open Market 09-Feb-2023 Completed Generating Revenue
14. Secondary Transaction - Open Market Completed Generating Revenue
13. PIPE 12-Aug-2019 Completed Generating Revenue
12. General Corporate Purpose 12-Mar-2018 Completed Generating Revenue
11. PIPE 22-Jul-2015 Completed Generating Revenue
10. 2PO 21-Jul-2015 $125M $263M Completed Generating Revenue
9. Debt - General 29-Dec-2014 $145M Completed Generating Revenue
To view Dynavax Technologies’s complete valuation and funding history, request access »

Dynavax Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's inna
Drug Discovery
Emeryville, CA
405 As of 2024

Paris, France
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dynavax Technologies Competitors (41)

One of Dynavax Technologies’s 41 competitors is Valerio Therapeutics, a Formerly VC-backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Valerio Therapeutics Formerly VC-backed Paris, France
Agenus Formerly VC-backed Lexington, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
VBI Vaccines Corporation Cambridge, MA
Zymeworks Formerly VC-backed Vancouver, Canada
You’re viewing 5 of 41 competitors. Get the full list »

Dynavax Technologies Patents

Dynavax Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026525284-A Lyme disease vaccine containing adjuvant and borrelia cell surface protein a antigen Pending 10-Jul-2023
AU-2024287849-A1 Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen Pending 10-Jul-2023
EP-4743109-A1 Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen Pending 10-Jul-2023
WO-2025015042-A1 Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen Inactive 10-Jul-2023
EP-4743110-A1 Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens Pending 10-Jul-2023 A61K39/39
To view Dynavax Technologies’s complete patent history, request access »

Dynavax Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dynavax Technologies Former Investors (38)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Majority
Axiom Venture Partners Venture Capital Minority
Azimuth Opportunity Investment Bank Minority
BVCF Venture Capital Minority
Bain Capital Life Sciences Corporate Venture Capital Minority
You’re viewing 5 of 38 investors. Get the full list »

Dynavax Technologies Acquisitions (2)

Dynavax Technologies’s most recent deal was a Merger/Acquisition with Symphony Dynamo for . The deal was made on 04-Jan-2010.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Symphony Dynamo 04-Jan-2010 Merger/Acquisition Pharmaceuticals
Rhein Biotech Merger/Acquisition Pharmaceuticals
To view Dynavax Technologies’s complete acquisitions history, request access »

Dynavax Technologies ESG

Risk Overview

Risk Rating

Updated November, 30, 2025

29.63 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view Dynavax Technologies’s complete esg history, request access »

Dynavax Technologies FAQs

  • When was Dynavax Technologies founded?

    Dynavax Technologies was founded in 1996.

  • Where is Dynavax Technologies headquartered?

    Dynavax Technologies is headquartered in Emeryville, CA.

  • What is the size of Dynavax Technologies?

    Dynavax Technologies has 405 total employees.

  • What industry is Dynavax Technologies in?

    Dynavax Technologies’s primary industry is Drug Discovery.

  • Is Dynavax Technologies a private or public company?

    Dynavax Technologies is a Private company.

  • What is the current valuation of Dynavax Technologies?

    The current valuation of Dynavax Technologies is .

  • What is Dynavax Technologies’s current revenue?

    The current revenue for Dynavax Technologies is .

  • How much funding has Dynavax Technologies raised over time?

    Dynavax Technologies has raised $693M.

  • Who are Dynavax Technologies’s investors?

    Alta Partners, Axiom Venture Partners, Azimuth Opportunity, BVCF, and Bain Capital Life Sciences are 5 of 38 investors who have invested in Dynavax Technologies.

  • Who are Dynavax Technologies’s competitors?

    Valerio Therapeutics, Agenus, Adaptimmune Therapeutics, VBI Vaccines, and Zymeworks are some of the 41 competitors of Dynavax Technologies.

  • When was Dynavax Technologies acquired?

    Dynavax Technologies was acquired on 10-Feb-2026.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process